Professor Sarah Fidler is a clinical academic who provides care for people living with HIV. Her main research interest is in the diagnosis, treatment and cure of HIV infection.
et al., 2022, HIV drug resistance in a community-randomized trial of universal testing and treatment: HPTN 071 (PopART), Journal of the International Aids Society, Vol:25
et al., 2022, The association between HIV stigma and HIV incidence in the context of universal testing and treatment: analysis of data from the HPTN 071 (PopART) trial in Zambia and South Africa, Journal of the International Aids Society, Vol:25
et al., 2022, Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV, Jci Insight, Vol:7
et al., 2022, The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial, Trials, Vol:23, ISSN:1745-6215
et al., 2022, HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana, Journal of Antimicrobial Chemotherapy, Vol:77, ISSN:0305-7453, Pages:1385-1395